JPMorgan Initiates Overweight on Tango Therapeutics with $46 Target as Pancreatic Cancer Data Impresses
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
/ 1648 items
#XY↓
Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Spero Sells Portion of Utebzi Economics for $105M to Fuel SP001 Development
Spero Therapeutics monetizes its Utebzi royalty stream in a $105M non-dilutive financing deal with Healthcare Royalty, extending cash runway to 2H 2029 while funding SP001 development.
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
HCA Healthcare Cuts 2026 Earnings Guidance as Uninsured Patient Surge Weighs on Profits
$400M pre-tax hit in Q2 as ACA subsidies expire.
Avere Therapeutics Debuts on Nasdaq Backed by Ex-Akero Leaders Behind Novo Nordisk Acquisition
The company just went public via a $320M reverse merger with NextCure and is advancing a promising once-weekly oral IL-23 inhibitor for psoriasis and ulcerative colitis.